MAPK-IN-5

• Description:

  MAPK-IN-5 is a potent MAPK inhibitor with an IC50 of 1.35 μM against HeLa cells. MAPK-IN-5 inhibits HeLa cell proliferation by inducing ROS-mediated DNA damage and mitochondrial apoptosis via the MAPK pathway. MAPK-IN-5 significantly inhibits colony formation, reduces the number of live cells, suppresses cell migration, and causes cell cycle arrest in the G2/M phase in HeLa cells. MAPK-IN-5 can be used for the study of cervical cancer[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; Bcl-2 Family; Caspase; p38 MAPK; PARP; Reactive Oxygen Species (ROS)

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Smiles:

  COCCOC (C=C1N=CN=C2NC3=CC (C (N=N4) =CN4CC5=CC=C (C (F) (F) F) C=C5) =CC=C3) =C (C=C12) OCCOC

• Molecular Formula:

  C30H29F3N6O4

• Molecular Weight:

  594.58

• References & Citations:

  [1]Wang L, et al. Design, synthesis and anti-cancer activity of novel 1,2,3-triazole hybrids of erlotinib against cervical cancer via MAPK signaling pathway. Sci Rep. 2025 Jul 9;15 (1) :24582.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Bcl-2; Caspase 3; Caspase 9; p38 MAPK; PARP1

• CAS Number:

  2579683-39-7